2014
DOI: 10.1007/s11102-014-0616-3
|View full text |Cite
|
Sign up to set email alerts
|

New oral anticoagulants and pituitary apoplexy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
10
0
4

Year Published

2015
2015
2021
2021

Publication Types

Select...
8
1
1

Relationship

2
8

Authors

Journals

citations
Cited by 19 publications
(14 citation statements)
references
References 5 publications
0
10
0
4
Order By: Relevance
“…In addition, it is suggested that pituitary gland might have a critical perfusion pressure well below normal arterial pressure (24). It is possible that this peculiar vascularity and sudden alterations in perfusion pressure by various triggering factors (Table 1) (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37), may predispose to sudden hemorrhage and/or infarction in micro adenomas as well as non-adenomatous lesions. Diabetes and arterial hypertension do not predispose patients to PA as reported in previous studies (16).…”
Section: Pathophysiologymentioning
confidence: 99%
“…In addition, it is suggested that pituitary gland might have a critical perfusion pressure well below normal arterial pressure (24). It is possible that this peculiar vascularity and sudden alterations in perfusion pressure by various triggering factors (Table 1) (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37), may predispose to sudden hemorrhage and/or infarction in micro adenomas as well as non-adenomatous lesions. Diabetes and arterial hypertension do not predispose patients to PA as reported in previous studies (16).…”
Section: Pathophysiologymentioning
confidence: 99%
“…New oral anticoagulants may also be involved [19, 20]. A precipitating role has been attributed also to the use of dopamine agonists (either at the beginning or after discontinuation of therapy) [21–28] and to oestrogen administration [29].…”
Section: Pathophysiologymentioning
confidence: 99%
“…PA has been observed after administration of anticoagulant drugs (vitamin K antagonist or platelet inhibitors) or thrombolytic agents, sometimes very soon after the initiation of treatment or after a prolonged period of treatment [6,9,47]. New classes of anticoagulant (dabigatran) [48,49] may also be involved.…”
Section: Anticoagulated Statesmentioning
confidence: 99%